What are the goals of pharmacotherapy in Crohn disease?

Updated: Jul 26, 2019
  • Author: Leyla J Ghazi, MD; Chief Editor: Praveen K Roy, MD, AGAF  more...
  • Print

The goals of pharmacotherapy in patients with Crohn disease are to reduce morbidity, to prevent complications, and to maintain nutritional status.

More recently, investigators reported the first use of a validated electrospray ionization LC-MS/MS method in human plasma for the simultaneous quantification of up to seven monoclonal antibodies (adalimumab, cetuximab, infliximab, rituximab, secukinumab, tocilizumab, and trastuzumab) acting against different pharmacologic targets. [152] This method has the potential to open up the field of therapeutic drug monitoring to many monoclonal antibodies, including for adalimumab, in patients with Crohn disease. [152]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!